Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

NORTHAMPTON, MA / / February 27, 2025 / In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income countries, this number ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Breast cancer remains a significant health challenge globally with approximately 2.3M new cases in 2022. While breast cancer ...

Yes, we know, it's still February and yet we can't stop going on about hiking sandals, but what can we say? Our toes are ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...